NCT06933381 Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
| NCT ID | NCT06933381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen's Medical Center |
| Condition | Reducing Pain With Nexplanon Implant Insertion |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-06-16 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Eligibility Criteria
Inclusion Criteria: * At least 14 years or older * Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402 * English speaking * Able and willing to sign the informed consent form and agree to terms of the study Exclusion Criteria: * Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure * Known previous exposure to vapocoolant spray * Nexplanon removal and reinsertion same day during visit in the same arm * Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane) * Unable to provide written, informed consent in English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06933381 clinical trial?
This trial is open to female participants only, aged 14 Years or older, studying Reducing Pain With Nexplanon Implant Insertion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06933381 currently recruiting?
Yes, NCT06933381 is actively recruiting participants. Contact the research team at smura@hawaii.edu for enrollment information.
Where is the NCT06933381 trial being conducted?
This trial is being conducted at Honolulu, United States, Honolulu, United States, Waimea, United States.
Who is sponsoring the NCT06933381 clinical trial?
NCT06933381 is sponsored by Queen's Medical Center. The trial plans to enroll 70 participants.